Salivary IgG To SARS-CoV-2 After Mild COVID-19
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A team of researchers has demonstrated that individuals exposed to SARS-CoV-2 have antibodies for the disease up to nine months after acquiring the disease, even if they displayed only mild symptoms.

The team used a multiplex bead-based array platform to investigate antibodies specific to SARS-CoV-2. They recruited saliva samples from convalescent patients from 1-9 months after symptomatic infection from SARS-CoV-2, undiagnosed self-reported individuals, and pre-pandemic reference samples.

The researchers noted four key findings. Firstly, and most importantly, SARS-CoV-2 specific salivary antibodies persist in the bloodstream for up to 9 months post-infection, even in mildly affected individuals. Additionally, after infection, salivary antibodies can recognize viral spikes and nucleocapsid proteins of SARS-CoV-2. They found that the body’s produced these antibodies in undiagnosed individuals who reported COVID disease-like symptoms.

Finally, that saliva Immunoglobulin G (IgG) is a stable protein that can tolerate both biosafety require temperature and detergent pre-treatment. The authors suggest that self-submitted salivary samples are a far less invasive and safer alternative to submitting immunity surveys, rather than subjecting potentially at-risk peoples to blood tests in laboratories. Their data also found that saliva samples can safely be inactivated with heat treatments or a commonly used detergent in laboratories.